Allergan's shareholders have approved the $63 billion takeover offer made by AbbVie, the U.S. biopharmaceutical company. The deal was announced on June 25 and is scheduled to close in early 2020, pending regulatory clearance. The U.S. Federal Trade Commission has asked both companies to provide additional information regarding the transaction.
Already an Eyewear Intelligence subscriber? Sign in here.
Buying a membership today will give you:
Or sign-up for a trial month for just 9,90€. To continue reading this article register now.